Fighting against the spread of AMR

    60
    (From left) Dr. Evan Payawal, senior medical manager, Pfizer Anti-Infectives; Dr. Rontgene Solante, infectious disease specialist; and Dr. Charmian Hufano, infectious disease specialist.
    (From left) Dr. Evan Payawal, senior medical manager, Pfizer Anti-Infectives; Dr. Rontgene Solante, infectious disease specialist; and Dr. Charmian Hufano, infectious disease specialist.
    0
    (0)

    In observance of World Antibiotic Awareness Week, Pfizer Philippines reaffirms its commitment to anti-microbial stewardship.

    Due to the improper use of antibiotics, antimicrobial resistance (AMR) among microorganisms like bacteria, viruses, and fungi – rendering medicines ineffective – is on the rise worldwide. As a result, infections are not treated and run the risk of spreading to others.

    AMR is a global threat not only to humans, but also to animals and the environment.

    The biopharmaceutical company is among the signatories of the Davos Declaration in 2016, committing to collective action for a sustainable market for antibiotics, vaccines and diagnostics.

    With other pharmaceutical companies, it endorses the Roadmap for Progress on Combating Antimicrobial Resistance, using a six-part strategy composed of stewardship, manufacturing, surveillance, vaccination, a supportive regulatory framework, and incentives and new business models to support research and development and a sustainable marketplace.

    These steps together can help reduce the spread of antimicrobial resistance.

    Dr. Rontgene Solante, infectious disease specialist, said AMR affects everyone, any age, any social class, all over the world. “It is a worldwide challenge,” he said.

    That is why programs by the Department of Health, and under the Universal Healthcare Law, include the proper distribution, administration, and taking of antibiotics, Solante said.

    “We need to be responsible as health industry workers, and the public, as people who consume medicines,” he pointed out.

    The biopharmaceutical company is driven by its desire to protect global public health and address the medical needs of people suffering from infectious diseases, said Dr. Evan Payawal, senior medical manager of Pfizer Anti-Infectives.

    Payawal said it is committed to become a leading provider of solutions to help prevent and treat infections through anti-microbial stewardship.

    The biopharmaceutical company called on not only health workers but also members of the general public to join the fight against the spread of AMR and take part in the global anti-microbial stewardship through simple acts like making sure they follow directions on the package, taking antibiotics only as prescribed by doctors, and washing your hands frequently.

    In this way, each Filipino can help contribute to stopping the spread of infection and increasing AMR incidence.

    According to a report prepared by the United Nations Interagency Coordinating Group on Antimicrobial Resistance, if left unchecked, AMR may contribute to 10 million deaths each year by the year 2050.

    In a bid to address the issue, the biopharmaceutical company currently offers one of the industry’s largest and most diverse portfolios of anti-infectives that includes more than 80 medicines.

    This portfolio contains therapies that help address areas of greatest unmet medical need.

    How useful was this article?